US-based MacuLogix Inc has raised $3.6m in Series A funding from Roche Venture Fund
Roche Venture Fund, the corporate venturing unit of the eponymous Switzerland-based pharmaceutical company, has participated in a $3.6m series A round for MacuLogix, an early diagnostics and tracking solutions for age-related macular degeneration company.
There was also involvement in the A round by Berwind Private Equity and venture capital firms Life Sciences Greenhouse and Ben Franklin Technology Partners.
The new funds will be used to accelerate manufacturing and commercial sales of the MacuLogix AdaptDx.
